Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M91.9Revenue (TTM) $M22.9Net Margin (%)-56.5Altman Z-Score-51.9
Enterprise Value $M154EPS (TTM) $-0.1Operating Margin %-10.4Piotroski F-Score5
P/E(ttm)--Beneish M-Score-7.0Pre-tax Margin (%)-61.7Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.1Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %-24.6Current Ratio0.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-100.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M161ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NAVB

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NAVB is held by these investors:



NAVB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-12-01Sell12,500$1.5-62view
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-11-02Sell12,500$1.98-71.21view
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-10-01Sell12,500$2.27-74.89view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-09-01Sell12,500$1.88-69.68view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-08-03Sell12,500$1.71-66.67view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-06-01Sell12,500$1.24-54.03view
Troup Gordon ADirector 2015-05-29Buy10,000$1.31-56.49view
FORD BRENDAN ADirector 2015-05-21Buy20,000$1.31-56.49view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-05-01Sell12,500$1.33-57.14view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-04-01Sell20,000$1.58-63.92view

Quarterly/Annual Reports about NAVB:

News about NAVB:

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 

More From Other Websites
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 13 2017
Why Navidea can recover no more than $12M if it wins against ex-lender in court Mar 13 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 09 2017
Navidea closes Lymphoseek sale to Cardinal Health; lender CRG accepts loan payment, drops liens Mar 06 2017
Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health Mar 03 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Mar 02 2017
Cardinal Health helps Navidea settle lender's payoff – for now Feb 24 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Feb 23 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Feb 16 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 10 2017
Navidea to Hold Conference Call to Provide Investor Update on Status of Ongoing Corporate Events Jan 27 2017
Navidea to Present at Upcoming Investor Conference Jan 06 2017
Navidea to Present at Upcoming Investor Conference Jan 06 2017
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : December 29, 2016 Dec 29 2016
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : December 13, 2016 Dec 13 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 30 2016
Edited Transcript of NAVB earnings conference call or presentation 3-Nov-16 12:30pm GMT Nov 28 2016
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : November 28, 2016 Nov 28 2016
Navidea Signs Asset Purchase Agreement with Cardinal Health Nov 23 2016
Navidea Signs Asset Purchase Agreement with Cardinal Health Nov 23 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)